JP2010526076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526076A5 JP2010526076A5 JP2010506507A JP2010506507A JP2010526076A5 JP 2010526076 A5 JP2010526076 A5 JP 2010526076A5 JP 2010506507 A JP2010506507 A JP 2010506507A JP 2010506507 A JP2010506507 A JP 2010506507A JP 2010526076 A5 JP2010526076 A5 JP 2010526076A5
- Authority
- JP
- Japan
- Prior art keywords
- crig
- antibody
- composition
- fragment
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims description 54
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims description 54
- 239000005557 antagonist Substances 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 22
- 244000052769 pathogen Species 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 17
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000003834 intracellular effect Effects 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 108010078015 Complement C3b Proteins 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000004087 circulation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91534007P | 2007-05-01 | 2007-05-01 | |
| PCT/US2008/061513 WO2008137338A1 (en) | 2007-05-01 | 2008-04-25 | CRIg ANTAGONISTS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526076A JP2010526076A (ja) | 2010-07-29 |
| JP2010526076A5 true JP2010526076A5 (https=) | 2012-05-31 |
Family
ID=39645433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506507A Pending JP2010526076A (ja) | 2007-05-01 | 2008-04-25 | ＣＲＩｇアンタゴニスト |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090162356A1 (https=) |
| EP (1) | EP2152749A1 (https=) |
| JP (1) | JP2010526076A (https=) |
| KR (1) | KR20100018523A (https=) |
| CN (1) | CN101675078A (https=) |
| AR (1) | AR066375A1 (https=) |
| AU (1) | AU2008247958A1 (https=) |
| BR (1) | BRPI0810926A2 (https=) |
| CA (1) | CA2682835A1 (https=) |
| CL (1) | CL2008001238A1 (https=) |
| IL (1) | IL201165A0 (https=) |
| MX (1) | MX2009011407A (https=) |
| PE (1) | PE20090239A1 (https=) |
| RU (1) | RU2009144280A (https=) |
| WO (1) | WO2008137338A1 (https=) |
| ZA (1) | ZA200906812B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| RU2553517C2 (ru) * | 2008-05-06 | 2015-06-20 | Дженентек, Инк. | Варианты crig с созревшей аффинностью |
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CN105924515B (zh) * | 2016-04-25 | 2019-06-14 | 中国人民解放军第三军医大学 | 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用 |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2019005817A2 (en) * | 2017-06-26 | 2019-01-03 | Bio-Techne Corporation | HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME |
| CN113423728B (zh) * | 2018-09-28 | 2024-03-01 | 优特力克斯有限公司 | 抗人vsig4抗体及其应用 |
| US20220233756A1 (en) * | 2019-05-17 | 2022-07-28 | George A. Herzlinger | Methods and systems for treating microbial disease |
| US20220306736A1 (en) * | 2019-09-04 | 2022-09-29 | Y-Biologics Inc. | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
| US20240158503A1 (en) | 2021-03-03 | 2024-05-16 | Pierre Fabre Medicament | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
| USD1121924S1 (en) * | 2023-12-08 | 2026-04-14 | 3Rd Wave Apparel Pty Ltd | Cap |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
-
2008
- 2008-04-25 BR BRPI0810926-5A2A patent/BRPI0810926A2/pt not_active IP Right Cessation
- 2008-04-25 WO PCT/US2008/061513 patent/WO2008137338A1/en not_active Ceased
- 2008-04-25 RU RU2009144280/10A patent/RU2009144280A/ru not_active Application Discontinuation
- 2008-04-25 US US12/150,220 patent/US20090162356A1/en not_active Abandoned
- 2008-04-25 CN CN200880014866A patent/CN101675078A/zh active Pending
- 2008-04-25 JP JP2010506507A patent/JP2010526076A/ja active Pending
- 2008-04-25 KR KR1020097024920A patent/KR20100018523A/ko not_active Withdrawn
- 2008-04-25 AU AU2008247958A patent/AU2008247958A1/en not_active Abandoned
- 2008-04-25 MX MX2009011407A patent/MX2009011407A/es active IP Right Grant
- 2008-04-25 EP EP08769166A patent/EP2152749A1/en not_active Withdrawn
- 2008-04-25 CA CA002682835A patent/CA2682835A1/en not_active Abandoned
- 2008-04-30 CL CL2008001238A patent/CL2008001238A1/es unknown
- 2008-04-30 AR ARP080101847A patent/AR066375A1/es not_active Application Discontinuation
- 2008-04-30 PE PE2008000774A patent/PE20090239A1/es not_active Application Discontinuation
-
2009
- 2009-09-24 IL IL201165A patent/IL201165A0/en unknown
- 2009-09-30 ZA ZA2009/06812A patent/ZA200906812B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526076A5 (https=) | ||
| RU2009144280A (ru) | АНТАГОНИСТЫ CRIg | |
| JP2011505867A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| JP2021515566A5 (https=) | ||
| JP2021533726A5 (https=) | ||
| JP2018506966A5 (https=) | ||
| JP2018035138A5 (https=) | ||
| JP2018535650A5 (https=) | ||
| JP2021516975A5 (https=) | ||
| JP2021515565A5 (https=) | ||
| JP2021516974A5 (https=) | ||
| JP2018500014A5 (https=) | ||
| JP2018521638A5 (https=) | ||
| RU2012153968A (ru) | Композиции и способы лечения инфекций и опухолей | |
| JP2018502840A5 (https=) | ||
| JP2017536341A5 (https=) | ||
| JP2011527902A5 (https=) | ||
| CA2952055A1 (en) | Monoclonal antibodies for ebola and marburg viruses | |
| JP2017534577A5 (https=) | ||
| FI2897981T3 (fi) | Anti-CD3-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:ta, ja niiden käyttöjä | |
| JP2018520334A5 (https=) | ||
| JP2015503909A5 (https=) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2017507657A5 (https=) |